Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 4871-4880 of 10980

Edit search filters
  1. Validation of Kinetic Activity Monitors (KAMs) in children

    Scottsdale/Phoenix, AZ

  2. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma

    Jacksonville, FL, Rochester, MN

  3. A Study to Optimize Endocrine Therapy Through Motivational Interviewing and Text Interventions

    Albert Lea, MN

  4. Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

    Rochester, MN

  5. A Study to Evaluate Autologous Adipose Derived Mesenchymal Stem Cells to Treat Spinal Cord Injury Patients

    Rochester, MN

  6. Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

    Rochester, MN

  7. A Study to Evaluate the Safety and Effectiveness of Endoluminal Clinical Treatment of Gastroesophageal Reflux Disease

    Jacksonville, FL

  8. A Study to Determine the Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

    Rochester, MN

  9. A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer

    Rochester, MN

.

Mayo Clinic Footer